Epigenetic alterations measured in blood may help guide breast cancer treatment. The multisite prospective study TBCRC 005 was conducted to examine the ability of a novel panel of cell-free DNA methylation markers to predict survival outcomes in metastatic breast cancer (MBC) using a new quantitative multiplex assay (cMethDNA).
INTRODUCTION
Significant therapeutic advances in the field of breast cancer have resulted in a growing number of treatment options for patients with metastatic breast cancer (MBC), and prioritization of these agents can be challenging. In practice, many months are often needed to determine whether the selected treatment is effective, a decision usually guided by clinical findings and imaging studies. The identification of highly accurate circulating molecular markers in blood that allows earlier evaluation of therapeutic benefit could help significantly in clinical decision making, minimize morbidity from ineffective therapy, reduce costs from additional imaging studies, and improve clinical outcomes. 1, 2 The current generation of circulating markers offers some prognostic usefulness but these are not predictive for clinical benefit from individual therapies. 3 Epigenetic alterations are among the most common molecular abnormalities in human cancers. 4 DNA methylation does not change the genomic DNA sequence and is a form of epigenetic alteration that is heritable during DNA replication. 5, 6 Tumors commonly release aberrant DNA into the bloodstream, and this can now be detected. Our group developed a highly sensitive high-throughput quantitative multiplex methylation-specific polymerase chain reaction assay named cMethDNA to detect circulating cell-free methylated DNA. 7 This assay builds on the prior assays we had used to detect methylation in tissue and in cytologic samples. [8] [9] [10] [11] A few clinical studies have since examined the association between the presence or absence of cellfree methylated DNA in peripheral blood and disease outcomes, but none have quantified the level of methylation. 7,12-15 TBCRC 005 is the first biomarker study designed specifically to prospectively test as a primary end point the role of DNA methylation in blood in predicting disease progression and survival in breast cancer.
PATIENTS AND METHODS

Study Design
Eligible participants included female patients $ 18 years of age with histologically confirmed MBC and measurable disease and an Eastern Cooperative Oncology Group performance status of 0 to 2, who were starting a new systemic therapy and being treated at one of seven participating US academic medical centers. Measurable/evaluable disease was defined as a lesion $ 1 cm on computed tomography scan or magnetic resonance imaging or a superficial/palpable lesion $ 2 cm. Patients with a diagnosis of a second cancer in the previous 5 years were excluded, with the exception of those women with basal or squamous cell carcinoma of the skin and/or cervical carcinoma in situ. All patients provided written informed consent. The institutional review board at each study site approved this study.
The study schema is outlined in Appendix Figure A1 (online only). Blood was collected at baseline, at week 4, and at first restaging (which was at the discretion of the treating oncologist). At all three time points, serum samples were processed locally and stored at 280°C within 4 hours of collection. The samples were then batched and shipped to Johns Hopkins, where they were stored at 280°C. Whole blood for analysis of circulating tumor cells (CTCs) was collected at baseline and at week 4 and was sent to the Clinical Laboratory Improvement Amendments-certified Clinical Chemistry Research Laboratory at Johns Hopkins for processing within 72 hours of collection.
Methylation and CTC Assays
The cMethDNA assay was used to measure duplicate samples of a methylation panel from a previously published 10-gene panel in 300 mL of serum. 7, 16 In addition, a set of identical quality control pooled specimens from approximately 5% of the total samples was inserted into every batch to assess inter-and intrabatch reproducibility. All samples from one individual were run in the same batch to minimize bias from interassay variability. Individual gene methylation (M) was calculated as a methylation index (MI):
MI ¼
No: methylated copies No: methylated þ gene standard copies ð100Þ
The MI of each sample was averaged across duplicates. The cumulative methylation index (CMI) is the sum of the MI for all genes. CTCs in 7.5 mL of whole blood were isolated and enumerated on the basis of the Janssen Diagnostic CellSearch System. Laboratory personnel were blinded to the ordering of samples and to all clinical information.
Statistical Analysis
Methylation data of each gene were log transformed after a small constant (0.1) was added to all values to account for zeros in the data. The inter-and intrabatch variation was evaluated using the coefficient of variation (CV) for all 10 genes and the CMI. Genes were selected for inclusion in the final analysis on the basis of CV, without reference to performance. Median progression-free survival (PFS) and overall survival (OS) with 95% CIs were estimated using the Kaplan-Meier method. Survival distributions were compared between patients with high and low CMIs at week 4 using the Gehan test, which gives more weight to early differences. Landmark analyses of PFS and OS were performed with the a priori defined time set at 4 weeks after treatment initiation. Patients who experienced disease progression or death before week 4 were excluded. Hazard ratios (HRs) and 95% CIs were estimated using the Cox proportional hazards models, controlling for age, ethnicity, prior therapy, phenotype, and disease burden. For classification of subjects into risk groups by CMI, a cut point was determined using an outcome-oriented approach for PFS and OS with a selection procedure that was based on the maximal log-rank statistic. 17 A two-fold cross-validation approach 18 was applied to confirm the significance of the cut point and to obtain almost unbiased estimates of the HR. The variability of the estimated HR using this approach was assessed by repeating the cross-validation 500 times with different choices of 1:1 random splits of the original data set.
Likelihood ratio tests were used in nested Cox models to assess the added value of each biomarker (CMI or CTCs at baseline or week 4) in predicting PFS and OS beyond established risk factors. The proportionality assumption was met by graphically assessing plots of log (2log [survival]) versus log of survival time. Because of the limited sample size, interaction terms (eg, potentially different effects of the biomarkers on outcomes by hormone receptor status) were examined using the Wald test but were not retained in the final models. The prognostic impact of the CMI according to each biologic subtype (hormone receptor and human epidermal growth factor receptor 2 status) was explored. Baseline and week 4 CMI, as well as change from baseline, were also evaluated as continuous markers with respect to outcomes. Disease status at first restaging was classified into one of three categories, progressive disease (PD), stable disease, or responsive disease (partial response/complete response) determined at approximately 8 to 12 weeks after the treatment started. The nonparametric Jonckheere-Terpstra trend test was used to assess whether week 4 CMI levels or reduction at week 4 from baseline differed among ordered disease status at first restaging. Association analyses of PD at first restaging (PD v non-PD) were performed using logistic regression.
All tests were two-sided and considered statistically significant at P , .05 and were performed using SAS 9.4 (SAS Institute, Cary, NC) and R version 3.1.0 (available at http://www.r-project.org).
RESULTS
A total of 182 women were enrolled in the study. Serum samples from the first 33 patients (taken before the start of sample collection for the CTC assay) were used for analytical validation of the cMethDNA assay, 7 leaving 149 women with available samples for this study. Of the 149 women, eight were excluded subsequently (Appendix Fig A2) , resulting in an analytic population of 141. Table 1 describes the patient characteristics of our analytic population. Serum was available to evaluate the CMI in duplicates at two time points (at baseline and at week 4) in 129 women, and at a third time point for 112 of the 129 women. Information on CTCs was available at baseline and at week 4 for 96 women. Median follow-up for the cohort was 19.5 months (range, 0.8 to 86.3 months).
The MI at baseline was calculated for all 10 genes (Appendix Fig A3) , and the results were highly correlated with one another (Appendix Table A1 , online only). Four of the genes (COL6A2, ARHGEF7, TMEFF2, and GXP7) were excluded from analyses because of CVs . 20%. The six genes included were AKR1B1, HOXB4, RASGRF2, RASSF1, HIST1H3C, and TM6SF1. The interand intrabatch CVs for any of the genes were , 18% (the majority having a CV , 10%), which is considered acceptable. 19 The interand intrabatch CVs for the CMI of the six genes were , 2.5%.
Landmark analyses were performed on the basis of week 4. A cut point of 9 for PFS and 21 for OS were the values selected for the week 4 CMI that maximized the log-rank statistic. One patient who had PD before the landmark time point was excluded. In the multivariable models described in Table 2 , patients with a high CMI at week 4 had a significantly worse PFS (HR, 1.79; 95% CI, 1.23 to 2.60; P = .002) after adjusting for age, ethnicity, prior therapy, tumor phenotype, and disease burden. Similar results for OS (HR, 1.75; 95% CI, 1.21 to 2.54; P = .003) are illustrated in Table 3 .
The median PFS among women in the high versus low CMI group was 2.1 months (95% CI, 1.7 to 3.2 months) versus 5.8 months (95%, CI 4.7 to 7.4 months), respectively ( Fig 1A) . The median OS was almost a year shorter for women in the high (12.3 months; 95% CI, 8.4 to 16.5 months) versus low (21.7 months; 95% CI, 19.3 to 28.3 months) CMI group ( Fig 1B) . Baseline CMI, modeled continuously, was not associated with PFS but was associated with OS in multivariate analyses (Appendix Fig A4) . The prognostic effect of the week 4 CMI was consistent across different biologic subtypes; however, the sample size of some subtypes was small (Appendix Table A2 ). Sensitivity analyses for factors such as body mass index, study site, and the 10-gene panel did not alter the observed estimates. To evaluate the robustness of the two-fold crossvalidation approach, we repeated the two-fold cross-validation procedure 500 times to allow for different choices of the 1:1 random split of the original data set and calculated the corresponding HR. The mean HR for PFS was 1.95 (variance, 0.048), and the mean HR for OS was 1.87 (variance, 0.023), which is considered stable and within the range of our original results.
The association between CMI levels at baseline, at week 4, and at first restaging and disease status as early as first restaging, which was most often at week 12, was also examined. Figure 2A illustrates the distributions of log CMI levels at baseline, at week 4, and at first restaging by disease status. A significant trend was observed between an increasing CMI at week 4 and less responsive disease at first restaging (P for trend , .001, Jonckheere-Terpstra test). The median CMI at week 4 was highest in women with PD, lowest in women with responsive disease (partial response/complete response), and intermediate in women with stable disease at first restaging.
Next, the effect on disease status of a change in CMI levels from baseline to week 4 was examined. Women with responsive (P , .001) or stable (P , .001) disease were more likely to have a reduction in median levels of the CMI from baseline to week 4 ( Fig 2A) . As illustrated in Tables 2 and 4 , a change in log CMI from baseline to week 4 was associated with worse PFS (HR, 1.21; 95% CI, 1.09 to 1.34; P , .001) and PD at first restaging (OR, 1.55; 95% CI, 1.20 to 2.01; P , .001). When a change in the CMI was modeled as a binary variable in multivariable analyses, an increase in the CMI at week 4 was associated with a worse PFS (HR, 2.18; 95% CI, 1.40 to 3.41; P , .001) and a 4.6-fold increase in the risk of PD at first restaging (OR, 4.58; 95% CI, 1.82 to 11.60; P = .001) compared with a reduction or no change in the CMI. In either case, adjusting for the baseline CMI did not alter the point estimates.
In this study, we were also able to evaluate CTCs at baseline and at week 4 in 96 women. The distribution of CTC values is illustrated in Appendix Figure A5 . As was the case with the CMI, week 4 CTCs $ 5 cells/7.5 mL were significantly associated with worse PFS (HR, 1.46; 95% CI, 1.02 to 2.10; P = .04) and OS (HR, 2.24; 95% CI, 1.54 to 3.26; P , .001). The median OS for $ 5 cells/7.5 mL was 8.1 months (95% CI, 4.9 to 18.8 months) and 20.8 months (95% CI, 17.5 to 26.6 months) for , 5 cells/7.5 mL. As was the case with the CMI, CTCs at week 4 were reduced in women with responsive disease (P = .0001; Fig 2B) . However, in contrast to CMI, CTC levels were not significantly different by disease status at first restaging (P for trend = .457; Fig 2B) . The CMI was more sensitive (78%) in identifying high-risk (progressive) disease than were CTCs (30%). A change in CTCs modeled either as a continuous marker (Appendix Fig A6) or as a binary marker (increase or reduction v no change from baseline; OR, 2.23; 95% CI, 0.77 to 2.47) was not significantly associated with PD at first restaging in multivariable analyses.
Finally, as an exploratory analysis, we examined the prognostic significance of the CMI and CTCs in 96 women in whom both markers had been measured (Appendix Table A3 ). Likelihood ratio tests suggest that the addition of either the week 4 CMI or CTCs significantly improved the ability of a model of established risk factors to predict PFS (P , .001and P = .038 for the CMI and CTCs, respectively) and OS (P = .043 and P = .007 for the CMI and CTCs, respectively). Furthermore, the CMI at week 4 seemed to be a significant predictor of PFS and improved the prediction of the base model even in the presence of CTCs (P = .004). In separate models, a change in the CMI in the base model improved PFS (P = .002), but a change in CTC level did not. The improvement with the change in the CMI occurred even in the presence of CTCs (P = .007). The addition of a change in CTC level or in the CMI did not significantly improve the model fit for OS.
DISCUSSION
To our knowledge, this is the first study to demonstrate the promise of early changes in the level of circulating cell-free tumor-specific DNA methylation for clinical application in patients with MBC.
Our results suggest that CMI levels of a novel six-gene panel measured 4 weeks after the initiation of a new therapy and a novel quantitative assay known as cMethDNA have clinical usefulness as a predictor of survival outcomes in women with MBC. A high CMI ‡High in this analysis is based on a week 4 CMI . 9. The remaining individuals were classified as low. level at week 4 was consistently associated with PFS and OS, as well as PD, as early as first restaging. Furthermore, a change in the CMI within 4 weeks of initiating therapy tracked with PFS and disease response as early as first restaging, supporting the potential prognostic usefulness of measuring CMI levels within weeks of initiating a new therapy. Last, both the CMI at week 4 and a change in the CMI added to the ability of established risk factors, including CTCs, to predict PFS. The six-gene panel examined in this study is based on the results of a DNA methylation array conducted in breast tumors and sera for patients with both estrogen receptor-positive and estrogen receptor-negative breast cancer. 7 Five of the six genes in the six-gene panel were identified by our group as methylated in breast cancer. 7 Two genes with some degree of commonality in function were RASGRF1, a RAS guanosine triphosphate hydrolase with nucleotide exchange function, 20 and RASSF1, a methylation marker common to many cancers that encodes a protein similar to RAS effector proteins. 21 Among the four other novel genes, HIST1H3C interacts with linker DNA between nucleosomes and functions in the compaction of chromatin into higher-order structures, 22 the AKR1B1 gene encodes a member of the aldo/keto reductase superfamily and catalyzes the reduction of a number of aldehydes, 23 and HOXB4 encodes a transcription factor involved in development and, as with many members of the HOX gene family, is regulated by methylation of dense C-phosphate-G islands. 24 There is no literature regarding the function of the newly discovered TM6SF1. 7 The cMethDNA assay can measure methylation levels in gene loci coamplified from one 300-mL aliquot of serum. The cMethDNA assay is calibrated against a low fixed physiologic level of recombinant gene-specific reference DNA that is copurified and coamplified with target methylated DNA. 7 A few other studies have evaluated the relationship between cell-free tumor DNA in plasma and serum and disease outcome in patients with breast cancer. [12] [13] [14] [15] [25] [26] [27] [28] Those studies did not quantify the level of methylation either as a categorical or as a continuous measure, as we report in this article. Most of the studies were based in a single institution, measured a limited number of candidate genes at a single time point, had a small sample size, included limited clinical information, and were not prospective. In our comparison of the CMI with CTCs, a clinically available biomarker for risk stratification in patients with breast cancer, the CMI and CTCs at week 4 seem to be complementary as prognostic markers, but both the CMI and a change in the CMI were stronger predictors of PFS when contrasted directly with CTCs. 29, 30 When predicting treatment response at first restaging, CTCs were more specific (85%) in identifying low-risk (stable or responsive) disease compared with the CMI (51%), whereas the CMI was more sensitive (78%) in identifying high-risk (progressive) disease than were CTCs (30%). Of interest, numeric changes in CTC level between baseline and week 4 were not associated with treatment response. Women with a high CTC level at both baseline and week 4 compared with those with a low CTC level had a worse PFS and OS; this finding is consistent with a recent clinical trial in MBC in which change in treatment guided by CTCs did not influence disease outcome. 30 Although monitoring for the change in the CMI for treatment response has prognostic usefulness, its clinical usefulness in influencing changes in therapy must now be evaluated formally in randomized clinical trials. Furthermore, whether there is meaningful risk reclassification of patients with the addition of the CMI is worth careful assessment in future larger validation studies.
To our knowledge, this is the first prospective study to demonstrate the potential clinical usefulness of measures of serum methylation to inform clinical care in breast cancer. The CMI of a panel of six genes and change in CMI levels were independent predictors of survival outcomes. Limitations of the study include the lack of central adjudication for outcomes such as PD, although these results seem to align with death, a less subjective outcome. Other limitations include the lack of blood samples before week 4 and the modest sample size. Our findings must be validated to determine the clinical usefulness of the cMethDNA assay for specific treatments and tumor phenotypes in patients with metastatic disease and early-stage breast cancer.
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